Evidence map›Paper›PMID 34751893›Full record

ArticleMetabolic brain disease2022

Quercetin mitigates scopolamine-induced memory dysfunction: impact on oxidative stress and cholinergic mechanisms.

Juliet N Olayinka, Anthony Eduviere, Olusegun Adeoluwa, Elizabeth Akinluyi, Abiola Obisesan, Oluwole Akawa, Adeshina Adebanjo

Abstract read
PubMed Publisher
In one paragraph

Article in Metabolic brain disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Neuroprotective properties ofIBRO neuroscience reports · 2026
    Article
  2. Review
  3. Protective Effects of a Propolis-Journal of microbiology and biotechnology · 2026
    Article
  4. Proanthocyanidins fromFrontiers in pharmacology · 2025
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Juliet N OlayinkaDepartment of Pharmacology and Therapeutics, College of Medicine and Health Sciences, Afe- Babalola University, Ado-Ekiti, Ekiti State, Nigeria. julietolayinka@abuad.edu.ng.ORCID 0000-0002-5663-0015
Anthony EduviereDepartment of Pharmacology and Therapeutics, Faculty of Basic Medical Sciences, Delta State University, Abraka, Nigeria.
Olusegun AdeoluwaDepartment of Pharmacology and Therapeutics, College of Medicine and Health Sciences, Afe- Babalola University, Ado-Ekiti, Ekiti State, Nigeria.
Elizabeth AkinluyiDepartment of Pharmacology and Therapeutics, College of Medicine and Health Sciences, Afe- Babalola University, Ado-Ekiti, Ekiti State, Nigeria.
Abiola ObisesanDepartment of Pharmacology and Therapeutics, College of Medicine and Health Sciences, Afe- Babalola University, Ado-Ekiti, Ekiti State, Nigeria.
Oluwole AkawaDepartment of Pharmacology and Therapeutics, College of Medicine and Health Sciences, Afe- Babalola University, Ado-Ekiti, Ekiti State, Nigeria.
Adeshina AdebanjoDepartment of Civil Engineering, Afe Babalola University, Ado-Ekiti, Ekiti State, Nigeria.
Afe Babalola University · NGDelta State University · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the promising neuroprotective activities of quercetin (QT), its' effect on cholinergic neurotransmission needs further elucidation. In this study, we explored the impact of QT on oxidative stress and cholinergic neurotransmission with emphasis on the possible involvement of choline acetyltransferase (ChAT) as a potential mechanism of QT on memory function at the hippocampal sub-regions and prefrontal cortex of mice brains. Mice were administered orally with QT (12.5 and 25 mg/kg) alone or in combination with SC (3 mg/kg, intraperitoneally) once daily for seven consecutive days. Thirty minutes after the last treatment, memory function was assessed using the Y-maze test. Levels of biomarkers of oxidative stress and acetylcholinesterase (AChE) activity were determined using a microplate reader. ChAT activity was determined by immunohistochemistry. QT pretreatment enhanced memory performance and reversed scopolamine (SC)-induced memory impairment in the Y-maze test. QT also reduced malondialdehyde and nitrite levels in mice brains. Glutathione levels were increased in mice brains as a result of QT administration. Levels of antioxidant enzymes (superoxide dismutase and catalase) were significantly increased in the mice brains, but AChE activity was reduced by QT. The activity of ChAT was significantly enhanced by QT in the hippocampal sub-regions and the prefrontal cortex of the mice brains. This study has shown that QT mitigated SC-induced memory dysfunction by inhibiting oxidative stress and AChE activity. Also, QT enhanced ChAT activity, particularly in the hippocampal sub-regions and the prefrontal cortex. These mechanisms, may be possible means through which QT improves memory performance.

Indexed as

QuercetinScopolamineAcetylcholinesteraseAnimalsCholinergic NeuronsHippocampusMaze LearningMemory DisordersMiceOxidative StressAcetylcholinesteraseQuercetinScopolamineAcetylcholinesterase activityCholine acetyltransferase activityCognitive impairmentOxidative stressQuercetin

Identifiers

PMID34751893
OpenAlexW3214257375

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.